BIOMAT Database Logo BIOMAT Database Logo

Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. 1998

J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Department of Obstetrics and Paediatrics, University of Natal, Durban, South Africa. moodleyj@med.und.ac.az@relay

The safety, pharmacokinetics, and antiretroviral activity of lamivudine alone and in combination with zidovudine was studied in pregnant women infected with human immunodeficiency virus type 1 (HIV-1) and their neonates. Women received the drugs orally from week 38 of pregnancy to 1 week after delivery. Neonate therapy began 12 h after delivery and continued for 1 week. Both treatment regimens were well-tolerated in women and newborns. Lamivudine and zidovudine pharmacokinetics in pregnant women were similar to those in nonpregnant adults. Lamivudine and zidovudine freely crossed the placenta and were secreted in breast milk. Neonatal lamivudine clearance was about half that in pediatric patients; zidovudine clearance was consistent with previous reports. HIV-1 RNA could be quantified in 17 of the 20 women. At the onset of labor/delivery, mean virus load had decreased by approximately 1.5 log10 copies/mL in both treatment cohorts. Although not definitive for HIV-1 infection status, all neonates had HIV-1 RNA levels below the limit of quantification at birth and at ages 1 and 2 weeks.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008895 Milk, Human Milk that is produced by HUMAN MAMMARY GLANDS. Breast Milk,Human Milk,Milk, Breast
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates.
March 2009, Antimicrobial agents and chemotherapy,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
February 1997, The Journal of pediatrics,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients.
January 2003, Antimicrobial agents and chemotherapy,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Disposition of zidovudine in obese pregnant women with human immunodeficiency virus type 1 infection.
September 1996, The Journal of infectious diseases,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Systemic pharmacokinetics and cellular pharmacology of zidovudine in human immunodeficiency virus type 1-infected women and newborn infants.
December 1999, The Journal of infectious diseases,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women.
November 1999, Obstetrics and gynecology,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Combination antiretroviral therapy in human immunodeficiency virus-infected pregnant women.
April 2000, Obstetrics and gynecology,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Coadministration of indinavir and nelfinavir in human immunodeficiency virus type 1-infected adults: safety, pharmacokinetics, and antiretroviral activity.
December 2002, Antimicrobial agents and chemotherapy,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Evaluation of IGF-2/ApaI polymorphism in pregnant women infected with human immunodeficiency virus type 1 taking antiretroviral drugs.
December 2009, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society,
J Moodley, and D Moodley, and K Pillay, and H Coovadia, and J Saba, and R van Leeuwen, and C Goodwin, and P R Harrigan, and K H Moore, and C Stone, and R Plumb, and M A Johnson
Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
April 2001, The Journal of infectious diseases,
Copied contents to your clipboard!